Scarica l'app Stockscreener
0.6094
2.82%
0.0167
Aprea Therapeutics Inc Borsa (APRE) Ultime notizie
Will Aprea Therapeutics Inc. stock go up in YEARJuly 2025 Sentiment & High Conviction Investment Ideas - mfd.ru
Aprea Therapeutics strengthens global patent portfolio in DNA Damage Response (DDR) cancer therapeutics - marketscreener.com
Aprea Therapeutics Strengthens Global Patent Portfolio In Dna Damage Response (Ddr) Cancer Therapeutics - TradingView
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth - The Manila Times
Aprea Therapeutics Expands Global Patent Portfolio for WEE1 and ATR Programs, Securing Exclusivity Through 2045 - Quiver Quantitative
Cancer therapy company Aprea wins patents guarding new treatments into 2045 - Stock Titan
Doylestown’s Aprea Therapeutics Names Industry Veteran as Chief Medical Advisor - BUCKSCO.Today
What hedge funds are buying Aprea Therapeutics Inc.Quarterly Profit Summary & Growth Focused Stock Reports - mfd.ru
Aprea taps veteran oncologist as clinical momentum builds for lead cancer drug - MSN
Aprea Taps Veteran Oncologist as Clinical Momentum Builds for Lead Cancer Drug - MyChesCo
Early cancer signal emerges as Aprea drug shrinks tumors in phase 1 trial - MSN
Aprea Therapeutics appoints Eugene Kennedy as chief medical advisor By Investing.com - Investing.com Nigeria
Aprea Therapeutics, Inc. Appoints Eugene Kennedy as Chief Medical Advisor - marketscreener.com
Aprea Therapeutics Appoints Eugene Kennedy, MD, as Chief Medical Advisor - citybiz
Aprea Therapeutics appoints Eugene Kennedy as chief medical advisor - Investing.com
Aprea Therapeutics Appoints New Chief Medical Advisor - Intellectia AI
Aprea Therapeutics Appoints Dr. Eugene Kennedy as Chief Medical Advisor to Enhance Oncology Program Development - Quiver Quantitative
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor - The Manila Times
Early Cancer Signal Emerges as Aprea Drug Shrinks Tumors in Phase 1 Trial - MyChesCo
Aprea Therapeutics (APRE) CEO buys $25,000 in shares By Investing.com - Investing.com South Africa
Aprea Therapeutics (APRE) CEO buys $25,000 in shares - Investing.com
HC Wainwright Has Bullish Forecast for APRE FY2026 Earnings - Defense World
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Aprea Therapeutics (APRE) - The Globe and Mail
Is FinWise Bancorp in a bullish channelEarnings Overview Report & Daily Market Momentum Tracking - baoquankhu1.vn
Short Squeeze: How cyclical is Aprea Therapeutics Incs revenue streamJuly 2025 Rallies & Risk Controlled Stock Alerts - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Aprea Therapeutics raises $5.6 million in private placement By Investing.com - Investing.com Nigeria
Aprea Therapeutics Announces Financing and Early Trial Response - The Globe and Mail
Aprea reports first partial response in Phase 1 cancer drug trial By Investing.com - Investing.com South Africa
Aprea Therapeutics Signs Multiple Material Agreements - TradingView
Aprea Therapeutics (APRE) Price Target Lowered to $4.00 by HC Wa - GuruFocus
What is Aprea Therapeutics Inc.’s market position2025 Valuation Update & Long Hold Capital Preservation Plans - mfd.ru
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Aprea reports first partial response in Phase 1 cancer drug trial - Investing.com Australia
Aprea Therapeutics Shares Slide After Phase 1 Cancer Drug Results Disappoint - StockInvest.us
Aprea Therapeutics stock falls after early-stage cancer drug data By Investing.com - Investing.com Nigeria
Aprea Therapeutics stock falls after early-stage cancer drug data - Investing.com
Aprea Therapeutics prices $5.6M private placement - MSN
Aprea Therapeutics raises $5.6 million in private placement - Investing.com
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan - The Manila Times
Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules - The Manila Times
Aprea Therapeutics Reports Early Clinical Activity of APR-1051 in Advanced Endometrial Cancer with Significant Tumor Reduction - Quiver Quantitative
Experimental cancer drug APR-1051 shrinks tumor 50% in early Aprea trial - Stock Titan
Aprea Therapeutics, Inc. announced that it expects to receive $5.597083 million in funding - marketscreener.com
How cyclical is Aprea Therapeutics Inc.’s revenue streamJuly 2025 PreEarnings & AI Forecast Swing Trade Picks - mfd.ru
AI Stocks: Is MCHPs ROE strong enough2025 Key Highlights & Smart Swing Trading Techniques - baoquankhu1.vn
Aprea Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Fed Meeting: How cyclical is Purple Biotech Ltd Depositary Receipts revenue streamMarket Movers & Reliable Breakout Forecasts - baoquankhu1.vn
Analysts Are Bullish on Top Healthcare Stocks: Aprea Therapeutics (APRE), Arcellx Inc (ACLX) - The Globe and Mail
Profit Review: Is DGXX undervalued by DCF analysis2025 Earnings Surprises & Growth Focused Entry Point Reports - baoquankhu1.vn
New Strong Sell Stocks for January 19th - Zacks Investment Research
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):